Interleukin-10 paradox: A potent immunoregulatory cytokine that has been difficult to harness for immunotherapy

Cytokine

Volumn 74, Issue 1, 2015, Pages 27-34

  Saxena, Ankit ^a   Khosraviani, Sam ^a   Noel, Sanjeev ^a   Mohan, Divya ^a   Donner, Thomas ^a   Hamad, Abdel Rahim A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmunity; B cells; Fas pathway; Gld; Interleukin 10

Indexed keywords

FAS ANTIGEN; ILODECAKIN; IMMUNOGLOBULIN; INTERLEUKIN 10; INTERLEUKIN 10 RECEPTOR; RECOMBINANT INTERLEUKIN 10; IL10 PROTEIN, HUMAN; IL10 PROTEIN, MOUSE;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CROHN DISEASE; CYTOKINE RELEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HALF LIFE TIME; HUMAN; HUMORAL IMMUNITY; IMMUNOGLOBULIN PRODUCTION; IMMUNOREGULATION; IMMUNOTHERAPY; INFLAMMATORY BOWEL DISEASE; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTOPENIA; MONOCYTOSIS; MULTIPLE SCLEROSIS; NEUTROPHILIA; NONHUMAN; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; PSORIASIS; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; UNSPECIFIED SIDE EFFECT; ANIMAL; AUTOIMMUNE DISEASES; BIOSYNTHESIS; CLINICAL TRIAL (TOPIC); FEMALE; IMMUNOLOGY; NONOBESE DIABETIC MOUSE; PATHOPHYSIOLOGY;

MUS;

ANIMALS; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-10; MICE, INBRED NOD; MULTIPLE SCLEROSIS;

EID: 84930177232     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2014.10.031     Document Type: Article

References (136)

1. Fiorentino D.F., Bond M.W., Mosmann T.R. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989, 170:2081-2095.
2. Spits H., de Waal Malefyt R. Functional characterization of human IL-10. Int Arch Allergy Immunol 1992, 99:8-15.
3. Moore K.W., de Waal Malefyt R., Coffman R.L., O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001, 19:683-765.
4. Kasama T., Strieter R.M., Lukacs N.W., Lincoln P.M., Burdick M.D., Kunkel S.L. Interleukin-10 expression and chemokine regulation during the evolution of murine type II collagen-induced arthritis. J Clin Invest 1995, 95:2868-2876.
5. Persson S., Mikulowska A., Narula S., O'Garra A., Holmdahl R. Interleukin-10 suppresses the development of collagen type II-induced arthritis and ameliorates sustained arthritis in rats. Scand J Immunol 1996, 44:607-614.
6. Reich K., Garbe C., Blaschke V., Maurer C., Middel P., Westphal G., et al. Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of the epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation. J Invest Dermatol 2001, 116:319-329.
7. Rott O., Fleischer B., Cash E. Interleukin-10 prevents experimental allergic encephalomyelitis in rats. Eur J Immunol 1994, 24:1434-1440.
8. Pennline K.J., Roque-Gaffney E., Monahan M. Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse. Clin Immunol Immunopathol 1994, 71:169-175.
9. Kuhn R., Lohler J., Rennick D., Rajewsky K., Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993, 75:263-274.
10. Gasim S., Elhassan A.M., Khalil E.A., Ismail A., Kadaru A.M., Kharazmi A., et al. High levels of plasma IL-10 and expression of IL-10 by keratinocytes during visceral leishmaniasis predict subsequent development of post-kala-azar dermal leishmaniasis. Clin Exp Immunol 1998, 111:64-69.
11. Blanco P., Palucka A.K., Pascual V., Banchereau J. Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev 2008, 19:41-52.
12. Chomarat P., Rissoan M.C., Banchereau J., Miossec P. Interferon gamma inhibits interleukin 10 production by monocytes. J Exp Med 1993, 177:523-527.
13. Fillatreau S., Sweenie C.H., McGeachy M.J., Gray D., Anderton S.M. B cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002, 3:944-950.
14. Mehrotra P.T., Donnelly R.P., Wong S., Kanegane H., Geremew A., Mostowski H.S., et al. Production of IL-10 by human natural killer cells stimulated with IL-2 and/or IL-12. J Immunol 1998, 160:2637-2644.
15. Rhodes K.A., Andrew E.M., Newton D.J., Tramonti D., Carding S.R. A subset of IL-10-producing gammadelta T cells protect the liver from Listeria-elicited, CD8(+) T cell-mediated injury. Eur J Immunol 2008, 38:2274-2283.
16. Speiran K., Bailey D.P., Fernando J., Macey M., Barnstein B., Kolawole M., et al. Endogenous suppression of mast cell development and survival by IL-4 and IL-10. J Leukoc Biol 2009, 85:826-836.
17. Denning T.L., Kim G., Kronenberg M. Cutting edge: CD4+CD25+ regulatory T cells impaired for intestinal homing can prevent colitis. J Immunol 2005, 174:7487-7491.
18. Guichelaar T., ten Brink C.B., van Kooten P.J., Berlo S.E., Broeren C.P., van Eden W., et al. Autoantigen-specific IL-10-transduced T cells suppress chronic arthritis by promoting the endogenous regulatory IL-10 response. J Immunol 2008, 180:1373-1381.
19. Mauri C., Bosma A. Immune regulatory function of B cells. Annu Rev Immunol 2012, 30:221-241.
20. DiLillo D.J., Matsushita T., Tedder T.F. B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Ann N Y Acad Sci 2010, 1183:38-57.
21. Lampropoulou V., Calderon-Gomez E., Roch T., Neves P., Shen P., Stervbo U., et al. Suppressive functions of activated B cells in autoimmune diseases reveal the dual roles of Toll-like receptors in immunity. Immunol Rev 2010, 233:146-161.
22. Mauri C., Blair P.A. Regulatory B cells in autoimmunity: developments and controversies. Nat Rev Rheumatol 2010, 6:636-643.
23. Perona-Wright G., Mohrs K., Szaba F.M., Kummer L.W., Madan R., Karp C.L., et al. Systemic but not local infections elicit immunosuppressive IL-10 production by natural killer cells. Cell Host Microbe 2009, 6:503-512.
24. Koppelman B., Neefjes J.J., de Vries J.E., de Waal Malefyt R. Interleukin-10 down-regulates MHC class II alphabeta peptide complexes at the plasma membrane of monocytes by affecting arrival and recycling. Immunity 1997, 7:861-871.
25. D'Andrea A., Aste-Amezaga M., Valiante N.M., Ma X., Kubin M., Trinchieri G. Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 1993, 178:1041-1048.
26. Ito S., Ansari P., Sakatsume M., Dickensheets H., Vazquez N., Donnelly R.P., et al. Interleukin-10 inhibits expression of both interferon alpha- and interferon gamma- induced genes by suppressing tyrosine phosphorylation of STAT1. Blood 1999, 93:1456-1463.
27. Joss A., Akdis M., Faith A., Blaser K., Akdis C.A. IL-10 directly acts on T cells by specifically altering the CD28 co-stimulation pathway. Eur J Immunol 2000, 30:1683-1690.
28. Kotenko S.V. The family of IL-10-related cytokines and their receptors: related, but to what extent?. Cytokine Growth Factor Rev 2002, 13:223-240.
29. Taniyama T., Takai S., Miyazaki E., Fukumura R., Sato J., Kobayashi Y., et al. The human interleukin-10 receptor gene maps to chromosome 11q23.3. Hum Genet 1995, 95:99-101.
30. Lutfalla G., Gardiner K., Uze G. A new member of the cytokine receptor gene family maps on chromosome 21 at less than 35 kb from IFNAR. Genomics 1993, 16:366-373.
31. Wolk K., Witte E., Reineke U., Witte K., Friedrich M., Sterry W., et al. Is there an interaction between interleukin-10 and interleukin-22?. Genes Immun 2005, 6:8-18.
32. Wolk K., Kunz S., Witte E., Friedrich M., Asadullah K., Sabat R. IL-22 increases the innate immunity of tissues. Immunity 2004, 21:241-254.
33. Reineke U., Schneider-Mergener J., Glaser R.W., Stigler R.D., Seifert M., Volk H.D., et al. Evidence for conformationally different states of interleukin-10: binding of a neutralizing antibody enhances accessibility of a hidden epitope. J Mol Recognit 1999, 12:242-248.
34. Yoon S.I., Logsdon N.J., Sheikh F., Donnelly R.P., Walter M.R. Conformational changes mediate interleukin-10 receptor 2 (IL-10R2) binding to IL-10 and assembly of the signaling complex. J Biol Chem 2006, 281:35088-35096.
35. Yoon S.I., Jones B.C., Logsdon N.J., Harris B.D., Deshpande A., Radaeva S., et al. Structure and mechanism of receptor sharing by the IL-10R2 common chain. Structure 2010, 18:638-648.
36. Liu Y., Wei S.H., Ho A.S., de Waal Malefyt R., Moore K.W. Expression cloning and characterization of a human IL-10 receptor. J Immunol 1994, 152:1821-1829.
37. Tan J.C., Indelicato S.R., Narula S.K., Zavodny P.J., Chou C.C. Characterization of interleukin-10 receptors on human and mouse cells. J Biol Chem 1993, 268:21053-21059.
38. Tan J.C., Braun S., Rong H., DiGiacomo R., Dolphin E., Baldwin S., et al. Characterization of recombinant extracellular domain of human interleukin-10 receptor. J Biol Chem 1995, 270:12906-12911.
39. Roth I., Fisher S.J. IL-10 is an autocrine inhibitor of human placental cytotrophoblast MMP-9 production and invasion. Dev Biol 1999, 205:194-204.
40. Denning T.L., Campbell N.A., Song F., Garofalo R.P., Klimpel G.R., Reyes V.E., et al. Expression of IL-10 receptors on epithelial cells from the murine small and large intestine. Int Immunol 2000, 12:133-139.
41. Geginat J., Sallusto F., Lanzavecchia A. Cytokine-driven proliferation and differentiation of human naive, central memory, and effector memory CD4(+) T cells. J Exp Med 2001, 194:1711-1719.
42. Schottelius A.J., Mayo M.W., Sartor R.B., Baldwin A.S. Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding. J Biol Chem 1999, 274:31868-31874.
43. Dagvadorj J., Naiki Y., Tumurkhuu G., Hassan F., Islam S., Koide N., et al. Interleukin-10 inhibits tumor necrosis factor-alpha production in lipopolysaccharide-stimulated RAW 264.7 cells through reduced MyD88 expression. Innate Immun 2008, 14:109-115.
44. Chang J., Kunkel S.L., Chang C.H. Negative regulation of MyD88-dependent signaling by IL-10 in dendritic cells. Proc Natl Acad Sci USA 2009, 106:18327-18332.
45. Yamaoka K., Otsuka T., Niiro H., Nakashima H., Tanaka Y., Nagano S., et al. Selective DNA-binding activity of interleukin-10-stimulated STAT molecules in human monocytes. J Interferon Cytokine Res 1999, 19:679-685.
46. Thibodeau J., Bourgeois-Daigneault M.C., Huppe G., Tremblay J., Aumont A., Houde M., et al. Interleukin-10-induced MARCH1 mediates intracellular sequestration of MHC class II in monocytes. Eur J Immunol 2008, 38:1225-1230.
47. de Waal Malefyt R., Yssel H., de Vries J.E. Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation. J Immunol 1993, 150:4754-4765.
48. Akdis C.A., Joss A., Akdis M., Faith A., Blaser K. A molecular basis for T cell suppression by IL-10: CD28-associated IL-10 receptor inhibits CD28 tyrosine phosphorylation and phosphatidylinositol 3-kinase binding. FASEB J 2000, 14:1666-1668.
49. Go N.F., Castle B.E., Barrett R., Kastelein R., Dang W., Mosmann T.R., et al. Interleukin 10, a novel B cell stimulatory factor: unresponsiveness of X chromosome-linked immunodeficiency B cells. J Exp Med 1990, 172:1625-1631.
50. Llorente L., Zou W., Levy Y., Richaud-Patin Y., Wijdenes J., Alcocer-Varela J., et al. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 1995, 181:839-844.
51. Ragheb S., Li Y., Simon K., VanHaerents S., Galimberti D., De Riz M., et al. Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid. Mult Scler 2011, 17:819-829.
52. Kalechman Y., Gafter U., Da J.P., Albeck M., Alarcon-Segovia D., Sredni B. Delay in the onset of systemic lupus erythematosus following treatment with the immunomodulator AS101: association with IL-10 inhibition and increase in TNF-alpha levels. J Immunol 1997, 159:2658-2667.
53. Thompson-Snipes L., Dhar V., Bond M.W., Mosmann T.R., Moore K.W., Rennick D.M. Interleukin 10: a novel stimulatory factor for mast cells and their progenitors. J Exp Med 1991, 173:507-510.
54. MacNeil I.A., Suda T., Moore K.W., Mosmann T.R., Zlotnik A. IL-10, a novel growth cofactor for mature and immature T cells. J Immunol 1990, 145:4167-4173.
55. Schroder M., Meisel C., Buhl K., Profanter N., Sievert N., Volk H.D., et al. Different modes of IL-10 and TGF-beta to inhibit cytokine-dependent IFN-gamma production: consequences for reversal of lipopolysaccharide desensitization. J Immunol 2003, 170:5260-5267.
56. Grondal G., Gunnarsson I., Ronnelid J., Rogberg S., Klareskog L., Lundberg I. Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 2000, 18:565-570.
57. Houssiau F.A., Lefebvre C., Vanden Berghe M., Lambert M., Devogelaer J.P., Renauld J.C. Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus 1995, 4:393-395.
58. Jacob S.E., Nassiri M., Kerdel F.A., Vincek V. Simultaneous measurement of multiple Th1 and Th2 serum cytokines in psoriasis and correlation with disease severity. Mediators Inflamm 2003, 12:309-313.
59. http://clinicaltrials.gov/ct2/home.
60. Atkinson M.A., Eisenbarth G.S. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001, 358:221-229.
61. Diagnosis and classification of diabetes mellitus Diabetes Care 2009, 32(Suppl 1):S62-S67.
62. Mueller D.L. Mechanisms maintaining peripheral tolerance. Nat Immunol 2010, 11:21-27.
63. Tindle R.W. Peripheral T-cell tolerance defined through transgenic mouse studies. Autoimmunity 2001, 33:135-149.
64. Zheng X.X., Steele A.W., Hancock W.W., Stevens A.C., Nickerson P.W., Roy-Chaudhury P., et al. A noncytolytic IL-10/Fc fusion protein prevents diabetes, blocks autoimmunity, and promotes suppressor phenomena in NOD mice. J Immunol 1997, 158:4507-4513.
65. Moritani M., Yoshimoto K., Ii S., Kondo M., Iwahana H., Yamaoka T., et al. Prevention of adoptively transferred diabetes in nonobese diabetic mice with IL-10-transduced islet-specific Th1 lymphocytes. A gene therapy model for autoimmune diabetes. J Clin Invest 1996, 98:1851-1859.
66. Wogensen L., Lee M.S., Sarvetnick N. Production of interleukin 10 by islet cells accelerates immune-mediated destruction of beta cells in nonobese diabetic mice. J Exp Med 1994, 179:1379-1384.
67. Lee M.S., Wogensen L., Shizuru J., Oldstone M.B., Sarvetnick N. Pancreatic islet production of murine interleukin-10 does not inhibit immune-mediated tissue destruction. J Clin Invest 1994, 93:1332-1338.
68. Lee M.S., Mueller R., Wicker L.S., Peterson L.B., Sarvetnick N. IL-10 is necessary and sufficient for autoimmune diabetes in conjunction with NOD MHC homozygosity. J Exp Med 1996, 183:2663-2668.
69. Balasa B., Van Gunst K., Jung N., Katz J.D., Sarvetnick N. IL-10 deficiency does not inhibit insulitis and accelerates cyclophosphamide-induced diabetes in the nonobese diabetic mouse. Cell Immunol 2000, 202:97-102.
70. Xiao Z., Mohamood A.S., Uddin S., Gutfreund R., Nakata C., Marshall A., et al. Inhibition of Fas ligand in NOD mice unmasks a protective role for IL-10 against insulitis development. Am J Pathol 2011, 179:725-732.
71. Thompson W.S., Pekalski M.L., Simons H.Z., Smyth D.J., Castro-Dopico X., Guo H., et al. Multi-parametric flow cytometric and genetic investigation of the peripheral B cell compartment in human type 1 diabetes. Clin Exp Immunol 2014, 177:571-585.
72. Herold K.C., Hagopian W., Auger J.A., Poumian-Ruiz E., Taylor L., Donaldson D., et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002, 346:1692-1698.
73. Song Y.W., Kang E.H. Autoantibodies in rheumatoid arthritis: rheumatoid factors and anticitrullinated protein antibodies. QJM 2010, 103:139-146.
74. Feldmann M., Brennan F.M., Maini R.N. Rheumatoid arthritis. Cell 1996, 85:307-310.
75. Choy E.H., Isenberg D.A., Garrood T., Farrow S., Ioannou Y., Bird H., et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 2002, 46:3143-3150.
76. Katsikis P.D., Chu C.Q., Brennan F.M., Maini R.N., Feldmann M. Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J Exp Med 1994, 179:1517-1527.
77. Cush J.J., Splawski J.B., Thomas R., McFarlin J.E., Schulze-Koops H., Davis L.S., et al. Elevated interleukin-10 levels in patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:96-104.
78. al-Janadi M., al-Dalaan A., al-Balla S., al-Humaidi M., Raziuddin S. Interleukin-10 (IL-10) secretion in systemic lupus erythematosus and rheumatoid arthritis: IL-10-dependent CD4+CD45RO+ T cell-B cell antibody synthesis. J Clin Immunol 1996, 16:198-207.
79. Bober L.A., Rojas-Triana A., Jackson J.V., Leach M.W., Manfra D., Narula S.K., et al. Regulatory effects of interleukin-4 and interleukin-10 on human neutrophil function ex vivo and on neutrophil influx in a rat model of arthritis. Arthritis Rheum 2000, 43:2660-2667.
80. van Roon J., Wijngaarden S., Lafeber F.P., Damen C., van de Winkel J., Bijlsma J.W. Interleukin 10 treatment of patients with rheumatoid arthritis enhances Fc gamma receptor expression on monocytes and responsiveness to immune complex stimulation. J Rheumatol 2003, 30:648-651.
81. Lacki J.K., Klama K., Mackiewicz S.H., Mackiewicz U., Muller W. Circulating interleukin 10 and interleukin-6 serum levels in rheumatoid arthritis patients treated with methotrexate or gold salts: preliminary report. Inflamm Res 1995, 44:24-26.
82. Chernoff A.E., Granowitz E.V., Shapiro L., Vannier E., Lonnemann G., Angel J.B., et al. A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J Immunol 1995, 154:5492-5499.
83. Maini RN, Paulus H, Breedveld PC. Hu lL-10 in subjects with active rheumatoid arthritis (I&A): phase I and cytokine response study. Arthritis Rheum. Abstract Supplement of National Scientific Meeting, Washington; 1997. p. 224.
84. Griffiths C.E., Barker J.N. Pathogenesis and clinical features of psoriasis. Lancet 2007, 370:263-271.
85. Stern R.S. Psoriasis. Lancet 1997, 350:349-353.
86. Nickoloff B.J., Fivenson D.P., Kunkel S.L., Strieter R.M., Turka L.A. Keratinocyte interleukin-10 expression is upregulated in tape-stripped skin, poison ivy dermatitis, and Sezary syndrome, but not in psoriatic plaques. Clin Immunol Immunopathol 1994, 73:63-68.
87. Mussi A., Bonifati C., Carducci M., Viola M., Tomaselli R., Sacerdoti G., et al. IL-10 levels are decreased in psoriatic lesional skin as compared to the psoriatic lesion-free and normal skin suction blister fluids. J Biol Regul Homeost Agents 1994, 8:117-120.
88. Asadullah K., Sterry W., Stephanek K., Jasulaitis D., Leupold M., Audring H., et al. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J Clin Invest 1998, 101:783-794.
89. Roberti M.L., Ricottini L., Capponi A., Sclauzero E., Vicenti P., Fiorentini E., et al. Immunomodulating treatment with low dose interleukin-4, interleukin-10 and interleukin-11 in psoriasis vulgaris. J Biol Regul Homeost Agents 2014, 28:133-139.
90. Asadullah K., Docke W.D., Ebeling M., Friedrich M., Belbe G., Audring H., et al. Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial. Arch Dermatol 1999, 135:187-192.
91. http://clinicaltrials.gov/ct2/show/study/NCT00001797?term=IL-10%26rank=7.
92. Loftus E.V., Sandborn W.J. Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am 2002, 31:1-20.
93. Sartor R.B. Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am J Gastroenterol 1997, 92:5S-11S.
94. Franke A., Balschun T., Karlsen T.H., Sventoraityte J., Nikolaus S., Mayr G., et al. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet 2008, 40:1319-1323.
95. Schreiber S., Heinig T., Thiele H.G., Raedler A. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology 1995, 108:1434-1444.
96. Correa I., Veny M., Esteller M., Pique J.M., Yague J., Panes J., et al. Defective IL-10 production in severe phenotypes of Crohn's disease. J Leukoc Biol 2009, 85:896-903.
97. Meresse B., Rutgeerts P., Malchow H., Dubucquoi S., Dessaint J.P., Cohard M., et al. Low ileal interleukin 10 concentrations are predictive of endoscopic recurrence in patients with Crohn's disease. Gut 2002, 50:25-28.
98. Wang A.H., Lam W.J., Han D.Y., Ding Y., Hu R., Fraser A.G., et al. The effect of IL-10 genetic variation and interleukin 10 serum levels on Crohn's disease susceptibility in a New Zealand population. Hum Immunol 2011, 72:431-435.
99. Kucharzik T., Stoll R., Lugering N., Domschke W. Circulating antiinflammatory cytokine IL-10 in patients with inflammatory bowel disease (IBD). Clin Exp Immunol 1995, 100:452-456.
100. Mitsuyama K., Tomiyasu N., Takaki K., Masuda J., Yamasaki H., Kuwaki K., et al. Interleukin-10 in the pathophysiology of inflammatory bowel disease: increased serum concentrations during the recovery phase. Mediators Inflamm 2006, 2006:26875.
101. Ljuca F., Gegic A., Salkic N.N., Pavlovic-Calic N. Circulating cytokines reflect mucosal inflammatory status in patients with Crohn's disease. Dig Dis Sci 2010, 55:2316-2326.
102. Ishizuka K., Sugimura K., Homma T., Matsuzawa J., Mochizuki T., Kobayashi M., et al. Influence of interleukin-10 on the interleukin-1 receptor antagonist/interleukin-1 beta ratio in the colonic mucosa of ulcerative colitis. Digestion 2001, 63(Suppl 1):22-27.
103. Colombel J.F., Rutgeerts P., Malchow H., Jacyna M., Nielsen O.H., Rask-Madsen J., et al. Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. Gut 2001, 49:42-46.
104. Fedorak R.N., Gangl A., Elson C.O., Rutgeerts P., Schreiber S., Wild G., et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 2000, 119:1473-1482.
105. Buruiana FE, Sola I, Alonso-Coello P. Recombinant human interleukin 10 for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2010: CD005109.
106. Shouval D.S., Biswas A., Goettel J.A., McCann K., Conaway E., Redhu N.S., et al. Interleukin-10 receptor signaling in innate immune cells regulates mucosal immune tolerance and anti-inflammatory macrophage function. Immunity 2014, 40:706-719.
107. Sattler S., Ling G.S., Xu D., Hussaarts L., Romaine A., Zhao H., et al. IL-10-producing regulatory B cells induced by IL-33 (Breg(IL-33)) effectively attenuate mucosal inflammatory responses in the gut. J Autoimmun 2014, 50:107-122.
108. Franciotta D., Salvetti M., Lolli F., Serafini B., Aloisi F. B cells and multiple sclerosis. Lancet Neurol 2008, 7:852-858.
109. Langrish C.L., Chen Y., Blumenschein W.M., Mattson J., Basham B., Sedgwick J.D., et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005, 201:233-240.
110. Tzartos J.S., Friese M.A., Craner M.J., Palace J., Newcombe J., Esiri M.M., et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008, 172:146-155.
111. Bar-Or A., Calabresi P.A., Arnold D., Markowitz C., Shafer S., Kasper L.H., et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 2008, 63:395-400.
112. Hauser S.L., Waubant E., Arnold D.L., Vollmer T., Antel J., Fox R.J., et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008, 358:676-688.
113. Blair P.A., Norena L.Y., Flores-Borja F., Rawlings D.J., Isenberg D.A., Ehrenstein M.R., et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity 2010, 32:129-140.
114. Bouaziz J.D., Calbo S., Maho-Vaillant M., Saussine A., Bagot M., Bensussan A., et al. IL-10 produced by activated human B cells regulates CD4(+) T-cell activation in vitro. Eur J Immunol 2010, 40:2686-2691.
115. Duddy M., Niino M., Adatia F., Hebert S., Freedman M., Atkins H., et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol 2007, 178:6092-6099.
116. Hirotani M., Niino M., Fukazawa T., Kikuchi S., Yabe I., Hamada S., et al. Decreased IL-10 production mediated by Toll-like receptor 9 in B cells in multiple sclerosis. J Neuroimmunol 2010, 221:95-100.
117. Porrini A.M., Gambi D., Reder A.T. Interferon effects on interleukin-10 secretion. Mononuclear cell response to interleukin-10 is normal in multiple sclerosis patients. J Neuroimmunol 1995, 61:27-34.
118. Rudick R.A., Ransohoff R.M., Peppler R., VanderBrug Medendorp S., Lehmann P., Alam J. Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis. Ann Neurol 1996, 40:618-627.
119. Chabot S., Yong V.W. Interferon beta-1b increases interleukin-10 in a model of T cell-microglia interaction: relevance to MS. Neurology 2000, 55:1497-1505.
120. Wang X., Chen M., Wandinger K.P., Williams G., Dhib-Jalbut S. IFN-beta-1b inhibits IL-12 production in peripheral blood mononuclear cells in an IL-10-dependent mechanism: relevance to IFN-beta-1b therapeutic effects in multiple sclerosis. J Immunol 2000, 165:548-557.
121. Kennedy M.K., Torrance D.S., Picha K.S., Mohler K.M. Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J Immunol 1992, 149:2496-2505.
122. Khoury S.J., Hancock W.W., Weiner H.L. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain. J Exp Med 1992, 176:1355-1364.
123. Issazadeh S., Mustafa M., Ljungdahl A., Hojeberg B., Dagerlind A., Elde R., et al. Interferon gamma, interleukin 4 and transforming growth factor beta in experimental autoimmune encephalomyelitis in Lewis rats: dynamics of cellular mRNA expression in the central nervous system and lymphoid cells. J Neurosci Res 1995, 40:579-590.
124. Nagelkerken L., Blauw B., Tielemans M. IL-4 abrogates the inhibitory effect of IL-10 on the development of experimental allergic encephalomyelitis in SJL mice. Int Immunol 1997, 9:1243-1251.
125. Cannella B., Gao Y.L., Brosnan C., Raine C.S. IL-10 fails to abrogate experimental autoimmune encephalomyelitis. J Neurosci Res 1996, 45:735-746.
126. Lisnevskaia L., Murphy G., Isenberg D. Systemic lupus erythematosus. Lancet 2014, [in press]. 10.1016/S0140-6736(14)60128-8.
127. Llorente L., Richaud-Patin Y., Wijdenes J., Alcocer-Varela J., Maillot M.C., Durand-Gasselin I., et al. Spontaneous production of interleukin-10 by B lymphocytes and monocytes in systemic lupus erythematosus. Eur Cytokine Netw 1993, 4:421-427.
128. Llorente L., Richaud-Patin Y., Fior R., Alcocer-Varela J., Wijdenes J., Fourrier B.M., et al. In vivo production of interleukin-10 by non-T cells in rheumatoid arthritis, Sjogren's syndrome, and systemic lupus erythematosus. A potential mechanism of B lymphocyte hyperactivity and autoimmunity. Arthritis Rheum 1994, 37:1647-1655.
129. Llorente L., Richaud-Patin Y., Couderc J., Alarcon-Segovia D., Ruiz-Soto R., Alcocer-Castillejos N., et al. Dysregulation of interleukin-10 production in relatives of patients with systemic lupus erythematosus. Arthritis Rheum 1997, 40:1429-1435.
130. Horwitz D.A., Gray J.D., Behrendsen S.C., Kubin M., Rengaraju M., Ohtsuka K., et al. Decreased production of interleukin-12 and other Th1-type cytokines in patients with recent-onset systemic lupus erythematosus. Arthritis Rheum 1998, 41:838-844.
131. Mongan A.E., Ramdahin S., Warrington R.J. Interleukin-10 response abnormalities in systemic lupus erythematosus. Scand J Immunol 1997, 46:406-412.
132. Hagiwara E., Gourley M.F., Lee S., Klinman D.K. Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin-10: interferon-gamma-secreting cells in the peripheral blood. Arthritis Rheum 1996, 39:379-385.
133. Rousset F., Garcia E., Defrance T., Peronne C., Vezzio N., Hsu D.H., et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA 1992, 89:1890-1893.
134. Lauwerys B.R., Garot N., Renauld J.C., Houssiau F.A. Interleukin-10 blockade corrects impaired in vitro cellular immune responses of systemic lupus erythematosus patients. Arthritis Rheum 2000, 43:1976-1981.
135. Llorente L., Richaud-Patin Y., Garcia-Padilla C., Claret E., Jakez-Ocampo J., Cardiel M.H., et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 2000, 43:1790-1800.
136. Huhn R.D., Radwanski E., Gallo J., Affrime M.B., Sabo R., Gonyo G., et al. Pharmacodynamics of subcutaneous recombinant human interleukin-10 in healthy volunteers. Clin Pharmacol Ther 1997, 62:171-180.